Company news
Supernus Pharmaceuticals, Inc. news in 2020
Supernus Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD
December 21, 2020
Supernus to Present at Two November Investor Conferences
November 10, 2020
Supernus Provides Regulatory Updates for SPN-812 and SPN-830
November 8, 2020
Supernus Announces Third Quarter 2020 Financial Results
November 2, 2020
Supernus to Host Third Quarter 2020 Financial Results Conference Call
October 26, 2020
Supernus Pharmaceuticals Appoints James Kelly as Chief Financial Officer
October 4, 2020
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two Treatments
September 13, 2020
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 8, 2020
Supernus to Present at the Wells Fargo Virtual Health Care Conference
September 1, 2020
Supernus Announces Second Quarter 2020 Financial Results
August 17, 2020
Supernus Announces Preliminary Second Quarter 2020 Revenue
August 10, 2020
Supernus Sues Apotex for Infringement of Oxtellar XR® Patents
June 25, 2020
Supernus Completes Acquisition of CNS Portfolio from US WorldMeds
June 8, 2020
Supernus to Present at the Jefferies Virtual Health Care Conference
May 26, 2020
Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR®
May 14, 2020
Supernus Announces First Quarter 2020 Financial Results
May 4, 2020
Supernus to Acquire CNS Portfolio from US WorldMeds
April 27, 2020
Supernus to Host First Quarter Results Earnings Conference Call
April 23, 2020
Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138
April 20, 2020
Supernus Provides Business Update
March 29, 2020
Supernus to Present at the 2020 Cowen Health Care Conference
February 25, 2020
Supernus Announces Fourth Quarter and Full Year 2019 Financial Results
February 24, 2020
Supernus to Host Fourth Quarter and Full Year 2019 Results Earnings Conference Call
February 10, 2020
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD
January 20, 2020
Supernus to Present at the 2020 J.P. Morgan Healthcare Conference
January 7, 2020
Calls in 2020
Decks in 2020
- Technical Presentation (December 2020)
Technical · 8 slides · Dec 23, 2020
- Merger or Acquisition (May 2020)
Merger or acquisition · 26 slides · May 4, 2020